WHO pointers involve manufacturers to apply a ongoing danger management process for sterility test isolators, like regular chance assessments and the event of danger-dependent Handle approaches. Manufacturers planning to carry out these approaches should present sturdy validation knowledge to show their equivalence to pharmacopoeial methods.